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The loss of normal regulation of corticosteroid secretion is important in the development of cardiovascular disease. We
previously showed that microRNAs regulate the terminal stages of corticosteroid biosynthesis. Here, we assess microRNA
regulation across the whole corticosteroid pathway. Knockdown of microRNA using Dicer1 siRNA in H295R
adrenocortical cells increased levels of CYP11A1, CYP21A1, and CYP17A1 mRNA and the secretion of cortisol,
corticosterone, 11-deoxycorticosterone, 18-hydroxycorticosterone, and aldosterone. Bioinformatic analysis of genes involved
in corticosteroid biosynthesis or metabolism identiﬁed many putative microRNA-binding sites, and some were selected for
further study. Manipulation of individual microRNA levels demonstrated a direct eﬀect of miR-125a-5p and miR-125b-5p
on CYP11B2 and of miR-320a-3p levels on CYP11A1 and CYP17A1 mRNA. Finally, comparison of microRNA expression
proﬁles from human aldosterone-producing adenoma and normal adrenal tissue showed levels of various microRNAs,
including miR-125a-5p to be signiﬁcantly diﬀerent. This study demonstrates that corticosteroidogenesis is regulated at
multiple points by several microRNAs and that certain of these microRNAs are diﬀerentially expressed in tumorous
adrenal tissue, which may contribute to dysregulation of corticosteroid secretion. These ﬁndings provide new insights into
the regulation of corticosteroid production and have implications for understanding the pathology of disease states where
abnormal hormone secretion is a feature.
1. Introduction
Cardiovascular disease is a major cause of mortality and
morbidity and therefore a key public health issue. The role
of the corticosteroids, aldosterone and cortisol, in the
modulation of blood pressure is well known. Their gross
excess results in hypertension, and this can be ameliorated
by pharmacological or surgical targeting of the production
and action of these steroid hormones [1, 2]. Even in essential
hypertension, blockade of these hormones lowers blood
pressure [3]. However eﬀorts to develop speciﬁc aldosterone
synthase inhibitors is limited, mostly due to its similarity to
11β-hydroxylase. An alternative approach to eﬀectively
reduce aldosterone production may be to target regulators
of CYP11B2 expression. Currently, our understanding of
the various mechanisms that control corticosteroid biosyn-
thesis in normal and pathological states is incomplete. This
must be improved if we are to develop more eﬀective
hypertension treatments.
Cortisol and aldosterone are the ﬁnal products of a series
of enzyme-controlled reactions that occur in the adrenal
cortex. Following transport of cholesterol to the mitochon-
drion, several cytochrome mixed function oxidases and
hydroxysteroid dehydrogenases, each encoded by speciﬁc
genes, control the integrated series of reactions (Figure 1)
culminating in the production of cortisol by 11β-hydroxy-
lase (CYP11B1) and aldosterone by aldosterone synthase
(CYP11B2) [4]. Cortisol can also be reversibly converted
to cortisone by 11β-hydroxysteroid dehydrogenases types
1 and 2 (HSD11B1, HSD11B2) [5, 6]. Some intermediate
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products in these pathways can themselves have deleteri-
ous cardiovascular eﬀects, such as the mineralocorticoid,
11-deoxycorticosterone [7].
Expression of corticosteroidogenic enzymes is tightly
controlled. This is regulated predominantly at the transcrip-
tional level, but studies by ourselves and others indicate that
posttranscriptional modiﬁcation by microRNA (miRNA)
also plays a signiﬁcant role [8–11]. miRNAs are endogenous
small noncoding RNAmolecules cleaved from intronically or
intergenically located primary miRNA (pri-miR) sequences.
Their transcription, in the form of a pri-miR, may be con-
trolled via host gene promoter activity or through a separate
miRNA promoter region [12]. They mature via a hairpin
structure called a pre-miR, to the ﬁnal miRNA, this last step
being catalysed by the Dicer enzyme [13]. Mature miRNAs
are incorporated into the RNA-induced silencing complex
(RISC) and use their speciﬁc sequence to bind imperfectly
to the 3′ untranslated region (UTR) of target mRNA. The
RISC contains several endonucleases which can repress
target mRNA levels through either translational repression
or mRNA degradation. Hence, miRNAs can ﬁne-tune levels
of mRNA and contribute to cellular homeostasis [14]. Each
step in the corticosteroidogenic pathway represents a
potential target for miRNA regulation. Furthermore, a single
miRNA is capable of regulating several constituents of a
single pathway [15] so that the sum of many small individual
eﬀects could result in pronounced changes overall.
Abnormal expression of speciﬁc miRNAs can be patho-
genic [14, 16]; miRNA levels are altered in adrenal carcinoma
and adenoma tissue when compared with normal adrenal
tissue [8, 17–23]. However, only a limited number of studies
have examined regulation of corticosteroidogenic genes by
miRNAs. Previously, we showed that knockdown of Dicer1
disrupted CYP11B1 and CYP11B2 mRNA levels in adreno-
cortical cells in vitro, pointing to a regulatory role for
miRNAs [8]. We identiﬁed miR-24 as one such miRNA
due—at least in part—to its regulatory eﬀects on CYP11B1
and CYP11B2 expression [8]. However, the eﬀect of this
individual miRNA on total corticosteroid biosynthesis is
small and numerous other miRNAs are likely to aﬀect
this pathway and probably not only at the terminal points
represented by these two genes [8, 10, 11]. The combined
regulatory impact of miRNAs simultaneously across all
the components of the corticosteroid pathway remains to
be assessed.
In this study, we expand the scope of our investigations to
encompass all of the genes directly contributing to corti-
costeroid production, including CYP11A1 and CYP17A1
(Figure 1). We demonstrate that Dicer1 knockdown by
siRNA aﬀects the corticosteroidogenic pathway in vitro at
numerous points, earlier than the terminal reactions we had
previously reported, and that these eﬀects are apparent at
both the mRNA and the steroid levels. We then analyse the
eﬀects of individual miRNAs on speciﬁc transcripts, guided
by bioinformatic analysis of gene sequence. Finally, we dem-
onstrate that certain of these corticosteroid-regulating miR-
NAs are diﬀerentially expressed in aldosterone-producing
adenoma tissue (APA). We propose that these miRNAs
may have a signiﬁcant pathogenic role and potential
diagnostic value.
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Figure 1: Pathway of corticosteroid synthesis in the adrenal cortex. Dashed lines represent the zone of the adrenal cortex in which each
reaction occurs.
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2. Materials and Methods
2.1. Cell Culture and Transfection. The H295R human
adrenocortical cell line (a gift from ProfessorWilliam Rainey,
Medical College of Georgia, USA) [24] and HeLa cells
(European Collection of Animal Cell Cultures, Wiltshire,
UK) were maintained as previously described [8] and used
between passage numbers 15 and 25. Cells were transfected
using siPORT NeoFX Transfection Agent (Applied Biosys-
tems, Warrington, UK) according to the manufacturer’s
instructions; H295R cells were seeded to a ﬁnal density of
4.8 × 105 cells/well in 6-well plates and HeLa cells to 8 ×104
cells/well in 24-well plates. Pre-miR™ or Anti-miR™ mole-
cules (miR-125a-5p: product code 12561; miR-125b-5p
miR-134-3p 10341; miR-495-3p: 11526; and miR-320a-3p:
11621, Applied Biosystems) were transfected to a ﬁnal con-
centration of 50 nM and prevalidated siRNA molecules
(Dicer 1A: product code s23755; Dicer 1B: s23756, Applied
Biosystems) to a ﬁnal concentration of 30nM. Reporter con-
structs were cotransfected with pEZX construct (500 ng) and
either a Pre-miR or an Anti-miR.
2.2. RNA Isolation and Real-Time Quantitative Reverse
Transcriptase PCR (qRT-PCR). Total RNA was isolated from
H295R cells using the miRNeasy mini kit (QIAGEN,
Crawley, UK) according to the manufacturer’s instructions.
First-strand cDNA was synthesised in a 20μL volume using
the miScript RT kit (QIAGEN) and 200ng of total RNA.
The resulting cDNA was diluted to a ﬁnal volume of 100μL
of which 2μL was ampliﬁed by qRT-PCR on the ABI
PRISM 7900HT apparatus (Applied Biosystems). Reactions
used themiScript SYBRGreenPCRkit (QIAGEN) tomeasure
mature miRNA-derived cDNA sequences and the Universal
ProbeLibrary System (Roche Applied Science, Indianapolis,
USA) and ABsolute™ QPCR ROX Mix (Abgene, Epsom,
UK) to measure mRNA cDNA using speciﬁc primer
sequences (Table 1).
2.3. Steroid Measurement. Steroids were extracted from cell
media using ChemElute cartridges (Varian) and eluted
from the cartridge with dichloromethane. The eluates
were evaporated to dryness and reconstituted in 10%
acetonitrile. Identiﬁcation and quantiﬁcation of steroid
products was achieved by tandem mass spectrometry
using a Varian 1200 L mass spectrometer with a triple
quadrupole detector [25].
2.4. Identiﬁcation of the Genomic Location of miRNAs and
Prediction of miRNA Targets. The genomic coordinates,
strand location, and mRNA transcript length of the human
genes encoding corticosteroidogenic enzymes were identiﬁed
using the Ensembl Genome Browser (release 79, March
2015). These were cross-referenced with known miRNA
precursor sequences mapped and stored in the miRBase
database (release 21, June 2014). Putative miRNA target sites
in the 3′UTRs of corticosteroidogenic genes were identiﬁed
by four commonly used prediction algorithms (MicroCosm
Targets (v.5), microRNA.org (Nov 2010), miRviewer (June
2005), and TargetScan (v. 6.2)).
2.5. Reporter Construct Studies. A luciferase reporter con-
struct was purchased from LabOmics (Nivelles, Belgium) to
determine miRNA binding to the 3′UTR. The construct
(pEZX-B2) contained a pEZX reporter backbone, which
comprises a renilla reporter gene coupled to a SV40 viral
promoter, a ﬁreﬂy experimental gene coupled to a CMV pro-
moter and the full-length 3′UTR sequence of the CYP11B2
gene. This was cotransfected with Pre-miR or Anti-miR into
HeLa cells; a “no-3′UTR insert” vector (pEZX-C) was used
as a control (LabOmics). Fireﬂy and renilla luciferase
activity was measured 48 hours posttransfection using
the Dual Luciferase Reporter Assay system (Promega,
Madison, USA) and a Lumat LB 9507 tube luminometer
(Berthold Technologies, Harpenden, UK).
2.6. Human Adrenal Gland miRNA Microarray Analysis.
Four frozen nondiseased predominantly cortical adrenal
tissue samples were obtained from white adult patients
undergoing nephrectomy, with full local ethical approval
from the University of Birmingham, UK. Four samples of
formalin-ﬁxed paraﬃn-embedded (FFPE) APA tissue were
obtained from the University of Glasgow Biobank. Use of
tissue in this study was conducted in accordance with the
requirements of the Human Tissue Act and with appropriate
permission from the local ethical review board. Participants
gave informed consent. Total RNA from 40mg frozen tissue
Table 1: Sequences of primers used in qRT-PCR assays.
Gene Forward primer Reverse primer
β-Actin CCAACCGCGAGAAGATGA CCAGAGGCGTACAGGGATAG
GAPDH GCTCTCTGCTCCTCCTGTTC ACGACCAAATCCGTTGACTC
StAR TACGTGGCTACTCAGCATCG ACCTGGTTGATGATGCTCTTG
CYP11A1 AGGAGGGGTGGACACGAC TTGCGTGCCATCTCATACA
CYP21A1 GAGGGCACAGTCATCATTCC GCTCCAGGAAGCGATCAG
CYP17A1 CTATGCTCATCCCCCACAG TTGTCCACAGCAAACTCACC
HSD3B2 AGGCCTTCAGACCAGAATTG CCTCAAGTACAGTCAGCTTGG
CYP11B1 ACTAGGGCCCATTTTCAGGT GGCAGCATCACACACACC
CYP11B2 GCACCTGCACCTGGAGATG CACACACCATGCGTGGTCC
HSD11B2 GGGTCAAGGTCAGCATCATC CACTGACCCACGTTTCTCAC
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samples or from four 20μm FFPE tissue sections was
prepared using the miRNeasy mini kit (QIAGEN) or the
RecoverAll™ Total Nucleic Acid Isolation kit (Applied
Biosystems) according to the manufacturer’s instructions,
respectively. miRNA microarray analyses for 723 miRNAs
(miRBase v 10.1) were performed by LC Sciences (Houston,
Texas, USA), using 5μg of the total RNA, as previously
described [8]; selected data from this study was previously
published [8].
2.7. Data Analysis. qRT-PCR results were analysed using the
relative quantiﬁcation method of comparative Ct (ΔΔCt)
[26]. In vitro results were analysed using either an unpaired
Student’s t-test or one-sample t-test as stated. Statistical
analysis was performed using Graph Pad Prism 6.0 software
and signiﬁcance reached when p < 0 05. All results are
expressed as mean± standard error of the mean (SEM).
Unless stated otherwise, in vitro experiments were performed
in at least three technical replicates, on three biologically
independent occasions (n = 3).
3. Results
3.1. siRNA Knockdown of Dicer1 Increases Levels of Selected
Steroidogenic mRNAs and Steroid Secretion in H295R Cells.
Signiﬁcant knockdown of Dicer1 mRNA by both Dicer1A
and Dicer1B siRNA transfection into the H295R adreno-
cortical cell line was demonstrated (0.56± 0.07-fold and
0.50± 0.06-fold, resp.; p < 0 001 for each versus scrambled
control siRNA) [8]. Total RNA was isolated 48 hours
posttransfection from cells transfected with scrambled
control siRNA or Dicer1A siRNA; levels of mRNAs were
measured by real-time qRT-PCR (Figure 2). Signiﬁcant
reduction in Dicer1 mRNA level did not signiﬁcantly aﬀect
the abundance of StAR, 3βHSDII, or HSD11B2 mRNAs,
but those of the three cytochrome P450-encoding mRNA
(CYP11A1, CYP21A1, and CYP17A1) were all signiﬁcantly
increased relative to cells transfected with a scrambled
control siRNA (1.41± 0.09-fold p < 0 05; 2.40± 0.34-fold,
p < 0 01; and 1.73± 0.22-fold, p < 0 01, resp.). Steroid
secretion from H295R cells was measured by LCMS
MS:MS 48 hours after transfection with a scrambled con-
trol or Dicer1B siRNA (Figure 3). Knockdown of Dicer1
signiﬁcantly increased secreted levels of cortisol (1.33±0.11-
fold; p = 0 01), corticosterone (1.32±0.13-fold; p = 0 03),
11-deoxycorticosterone (1.53±0.09-fold; p < 0 001), 18-
hydroxycorticosterone (1.29±0.10-fold; p = 0 04), and aldo-
sterone (1.47± 0.11-fold; p < 0 01) relative to scrambled
siRNA transfected cells. Levels of 11-deoxycortisol and
cortisone rose but did not achieve statistical signiﬁcance.
3.2. Corticosteroidogenic Genes Contain Putative 3′UTR
miRNA Target Sites. Putative miRNA binding sites were
identiﬁed in the 3′UTR in eachof the seven human corticoster-
oidogenic genes (CYP11B1, CYP11B2, CYP11A1, CYP17A1,
CYP21A2, HSD3B2, and StAR) and in the two metabolising
genes (HSD11B1, HSD11B2) analysed (Table 2). CYP11B1
has the longest 3′UTR (2022 base pairs) and contains
the highest number of putative miRNA binding sites
(390 sites). Conversely, CYP17A1 has the shortest 3′UTR
and the lowest number of predicted miRNA binding sites
(59 sites).
3.3. The miR-125 Family Regulates CYP11B2 mRNA
Expression. In order to identify individual miRNAs contrib-
uting to the net miRNA eﬀect, as observed under Dicer1
knockdown, four miRNAs (miR-125a-5p, miR-125b-5p,
miR-134-3p, and miR-495-3p) expressed in human adrenal
tissue and with putative binding sites in the 3′UTR of
CYP11B2 were selected for further study. Luciferase reporter
constructs containing the 3′UTR of CYP11B2 (pEZX-B2)
were transfected into HeLa cells alongside Pre-miR or Anti-
miR molecules speciﬁc to each of these miRNAs. Levels of
luciferase activity were then measured (Figures 4(a), 4(b),
4(c), and 4(d)). Manipulation of miR-134-3p or miR-495-
3p levels in this manner did not signiﬁcantly aﬀect the
luciferase activity of the pEZX-B2 reporter construct.
However, the presence of active binding sites predicted
for miR-125a-5p and miR-125b-5p was conﬁrmed by
changes in luciferase activity. Increasing the levels of
miR-125a-5p in Pre-miR-transfected cells reduced luciferase
activity to 63.78± 8.70% (p = 0 011) while reduction of miR-
125a-5p levels in Anti-miR-transfected cells signiﬁcantly
increased luciferase activity to 173.72± 22.54% (p = 0 040).
Similarly, miR-125b-5p Pre-miR signiﬁcantly decreased
luciferase activity (75.90± 1.28%; p = 0 033), while its Anti-
miR resulted in a signiﬁcant increase (156.39± 14.26%;
p = 0 017). These responses are consistent with canonical
miRNA action.
To determine the direct eﬀect of these miRNAs on
CYP11B2 mRNA expression, Pre-miR or Anti-miR mole-
cules were then transfected into the H295R adrenocortical
cell line. Here, miR-125a-5p Pre-miR decreased CYP11B2
mRNA abundance (0.69 ±0.002-fold; p < 0 0001), while
its Anti-miR signiﬁcantly increased it (1.62± 0.014-fold
p = 0 011; Figure 4(e)). miR-125b-5p Pre-miR transfection
reduced CYP11B2 mRNA to 0.75± 0.09 8-fold of con-
trol levels, but this did not attain statistical signiﬁcance
(p = 0 069). However, miR-125b-5p levels with Anti-miR
did signiﬁcantly increase CYP11B2 mRNA to 1.36±1 0.04-
fold (p = 0 041) of control levels (Figure 4(f)).
3.4. miR-320a Is a Common Regulator of CYP17A1 and
CYP11A1. Bioinformatic analysis predicted a miRNA bind-
ing site for miR-320a-3p in the 3′UTR of two corticosteroi-
dogenic genes: CYP11A1 and CYP17A1. This was tested by
transfecting H295R cells with miR-320a-3p Pre-miR and
Anti-miR molecules and then measuring mRNA 48 hours
posttransfection by qRT-PCR (Figure 5). Raising miR-
320a-3p led to signiﬁcantly decreased CYP11A1 mRNA
(0.81± 0.02-fold; p < 0 05) but did not signiﬁcantly aﬀect
CYP17A1 (1.02± 0.12-fold). Reduction of miR-320a-3p
levels in H295R cells signiﬁcantly increased both mRNAs:
CYP11A1 (1.40± 0.03-fold; p < 0 01) and CYP17A1 (1.53±
0.09-fold; p < 0 05).
3.5. miRNA Expression Diﬀers in Normal Adrenal Tissue and
Aldosterone-Producing Adenoma Tissue. In a previous study,
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miRNA expression was assessed by microarray analysis using
total RNA samples isolated from four nondiseased human
adrenal glands and four human aldosterone-producing
adenomas (APAs) [8]. Of the ﬁve miRNAs investigated
in the current study, two (miR-125a-5p and miR-495-3p)
were expressed at signiﬁcantly lower levels in APA tissue
relative to nontumorous tissue; one (miR-320a-3p) was
signiﬁcantly increased in APA tissue and two (miR-125b-5p
and miR-134-3p) did not diﬀer signiﬁcantly between the
tissue types (Figure 6).
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Figure 2: Results from Dicer1 siRNA transfection of H295R adrenocortical cells. Cells were transfected with Dicer1 siRNA or with a
scrambled negative-control siRNA (mRNA levels for StAR (a), CYP11A1 (b), 3βHSD11 (c), CYP21A (d), CYP17A1 (e), and HSD11B2 (f)
were analysed 48 hours posttransfection by qRT-PCR). Cycle threshold values were normalised to β-actin mRNA and expressed relative
to control cell levels. Results represent the mean of three independent biological experiments performed in triplicate± SEM; ∗p < 0 05,
∗∗p < 0 01 compared to scrambled control.
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4. Discussion
The in vitro investigations conducted during this and our
previous study [8] show that general reduction in miRNA
levels through knockdown of Dicer1 signiﬁcantly increases
the abundance of all cytochrome P450-encoding mRNAs in
this pathway (i.e., CYP11A1, CYP21A1, CYP17A1, CYP11B1,
and CYP11B2). This conﬁrms that miRNA can exert a net
inhibitory eﬀect on the expression of these key corticosteroi-
dogenic genes which is reﬂected in altered steroid proﬁle.
Dicer1 knockdown increased levels of 11-deoxycortisol,
corticosterone, 18-hydroxycorticosterone, cortisol, and aldo-
sterone although the change in 11-deoxycortisol did not
achieve statistical signiﬁcance. The lack of eﬀect on StAR
expression has already been reported [27]. Interestingly, the
dehydrogenase enzymes were not aﬀected; the HSD11B1
and HSD11B2 products control the interconversion of corti-
sol and cortisone in many target tissues, but their mRNA
levels were unaﬀected by Dicer1 knockdown. Moreover,
levels of cortisone were not signiﬁcantly altered. These two
genes and their respective products are not primary products
of the adrenal cortex, and while these enzymes do not appear
11-Deoxycortisol
Scr Dicer1
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
Fo
ld
 ch
an
ge
(r
el
at
iv
e t
o 
ne
ga
tiv
e c
on
tro
l)
(a)
Scr Dicer1
Fo
ld
 ch
an
ge
(r
el
at
iv
e t
o 
ne
ga
tiv
e c
on
tro
l)
Cortisol
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
⁎
(b)
Scr Dicer1
Fo
ld
 ch
an
ge
(r
el
at
iv
e t
o 
ne
ga
tiv
e c
on
tro
l)
Cortisone
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
(c)
Scr Dicer1
Fo
ld
 ch
an
ge
(r
el
at
iv
e t
o 
ne
ga
tiv
e c
on
tro
l)
Deoxycorticosterone
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75 ⁎⁎⁎
(d)
Scr Dicer1
Fo
ld
 ch
an
ge
(r
el
at
iv
e t
o 
ne
ga
tiv
e c
on
tro
l)
Corticosterone
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
⁎
(e)
Scr Dicer1
Fo
ld
 ch
an
ge
(r
el
at
iv
e t
o 
ne
ga
tiv
e c
on
tro
l)
18-OH-corticosterone
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
⁎
(f)
Scr Dicer1
Fo
ld
 ch
an
ge
(r
el
at
iv
e t
o 
ne
ga
tiv
e c
on
tro
l)
Aldosterone
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75 ⁎⁎
(g)
Figure 3: Results from Dicer1 siRNA transfection of H295R adrenocortical cells. Cells were transfected with Dicer1 siRNA or with a
scrambled negative-control siRNA. Cortisol-related steroid levels for 11-deoxycortisol (a), cortisol (b), and cortisone (c) and aldosterone-
related steroid levels for deoxycorticosterone (d), corticosterone (e), 18-OH-corticosterone (f), and aldosterone (g) were measured
48 hours posttransfection by LC MS:MS. Results represent the mean of three independent biological experiments performed in
triplicate± SEM; ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001 compared to scrambled control.
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Table 2: Bioinformatic miRNA target site predictions for corticosteroidogenic genes.
Gene
3′UTR length
(base pairs)
MicroRNA.org miRviewer TargetScan
MicroCosm
targets
Unique miRNAs
with binding sites
CYP11B1 2022 151 (142) 4 (4) 436 (333) 33 (30) 390
CYP11B2 1428 89 (83) 10 (10) 323 (253) 6 (6) 288
CYP11A1 213 26 (26) 1 (1) 51 (50) 43 (43) 68
CYP17A1 171 24 (24) 0 35 (34) 23 (22) 59
CYP21A2 508 57 (56) 11 (10) 78 (70) 25 (22) 134
HSD3B2 414 68 (63) 0 73 (68) 46 (44) 125
StAR 624 110 (101) 4 (4) 273 (244) 11 (11) 285
HSD11B1 343 167 (135) 1 (1) 79 (72) 70 (65) 159
HSD11B2 550 82 (78) 4 (4) 116 (104) 33 (31) 159
The 3′UTR lengths of these 9 genes were identiﬁed using the UCSCGenome Browser Gateway and Ensembl Genome Browser. The number of predictedmiRNA
target sites from each database is listed, and the number of unique miRNAs predicted to bind each is shown in parentheses. The ﬁnal column shows the
cumulative number of miRNA target sites, with duplicates removed.
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Figure 4: (a–d) Results from HeLa cells transfected with pEZX-B2 3′UTR reporter construct plasmids and either a speciﬁc miRNA Pre-miR
or Anti-miR, or with a scrambled negative control RNA. Fireﬂy and renilla luciferase luminescence was measured 48 hours posttransfection,
and results are presented as ﬁreﬂy reporter gene luminescence normalised for renilla luminescence. H295R cells transfected with either
miR-125a-5p (e) or miR-125b-5p (f) Pre-miR, miR-24 Anti-miR, or with a scrambled negative control RNA. CYP11B2 mRNA was
measured 48 hours posttransfection by qRT-PCR, with cycle threshold values normalised to GAPDH mRNA and expressed relative
to negative control. Results represent the mean of three independent biological experiments performed in triplicate± SEM; ∗p < 0 05,
∗∗∗p < 0 001 compared to negative control.
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subject to miRNA regulation in H295R cells, other studies
suggest miRNAs may regulate HSD11B1 and HSD11B2 in
other tissues where they have greater functionality [28, 29].
These results indicate that a general inhibition of miRNA
synthesis in H295R cells allows increased expression of most,
but not all, corticosteroidogenic mRNA transcripts and a rise
in steroid products.
Bioinformatic analysis identiﬁed putative miRNA target
sites in all of the genes tested, although the number of sites
predicted at each locus varied markedly depending on the
algorithm used. This variability is well known [30], and so
it is common to employ multiple algorithms in order to
reduce error, as was the case here. These algorithms examine
only 3′UTR sequences, and so do not identify possible
miRNA binding sites within coding regions or 5′UTR
[31, 32]. Therefore, our studies were restricted to miRNA
targeting of corticosteroidogenic mRNAs at the 3′UTR. We
also used bioinformatic tools to investigate whether the
introns of these nine genes harbour any of the 1881 currently
mapped human pri-miRNA sequences that occur through-
out the genome, but none was found (data not shown).
Therefore, any miRNA identiﬁed as controlling these genes
is not cotranscribed with them.
Since bioinformatic analysis identiﬁed miRNA 3′UTR
binding sites in all of the genes studied, it is not clear why
some genes are apparently refractory, other than to note that
predictive algorithms are not perfect, hence the need for
experimental veriﬁcation. Alternatively, structural diﬀer-
ences may determine susceptibility; in this study, cytochrome
P450 enzymes responded but dehydrogenases did not. More-
over, the 3′UTRs of the enzymes varied widely in their length
and number of binding sites they were predicted to contain.
Shorter 3′UTRs are thought to be more resistant to miRNA
regulation [33].
miR-125a-5p and miR-125b-5p (but not miR-134-3p or
miR-495-3p) altered CYP11B2 expression in vitro through
direct targeting of its transcript 3′UTR. These two miRNAs
belong to the same family, diﬀering by only one nucleotide.
However, miR-125a is located on human chromosome 19
in a cluster with miR-99b and let-7c, while miR-125b can
originate from either human chromosome 11 (miR-125b-1)
or human chromosome 21 (miR-125b-2). They are located
intergenically, and miR-125b-2 is close to a gene encoding a
long, noncoding RNA (lncRNA). The miR-125 family has
been implicated in the regulation of several cell types and
has many conﬁrmed targets, including vascular cell cycle-
Scr Pre-miR
Transfectant
Anti-miR
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
Fo
ld
 ch
an
ge
 C
Y
P
11
A
1 
m
RN
A
(n
or
m
al
ise
d 
to
 훽
-a
ct
in
,
re
la
tiv
e t
o 
co
nt
ro
l)
miR-320a-3p
⁎
⁎⁎
(a)
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
Fo
ld
 ch
an
ge
 C
Y
P
17
A
1 
m
RN
A
(n
or
m
al
ise
d 
to
 훽
-a
ct
in
,
re
la
tiv
e t
o 
co
nt
ro
l)
Scr Pre-miR
Transfectant
Anti-miR
miR-320a-3p
⁎
(b)
Figure 5: H295R cells transfected with miR-320a-3p Pre-miR, miR-320a-3p Anti-miR, or with a scrambled negative control RNA. CYP11A1
(a) or CYP17A1 (b) mRNA was measured 48 hours posttransfection by qRT-PCR, with cycle threshold values normalised to β-actin mRNA
and expressed relative to negative control. Results represent the mean of three independent biological experiments performed in triplicate±
SEM; ∗p < 0 05 and ∗∗p < 0 01 compared to negative control.
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Figure 6: Expression levels of ﬁve miRNAs in normal adrenal
tissue and APA tissue, as determined by microarray. Data show
the normalised microarray signals, with a threshold value of
>500 arbitrary units (AU) for at least one tissue type; ∗p < 0 05,
∗∗∗p < 0 001.
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related genes of importance in hypertension [34, 35].
CYP11A1 and CYP17A1 are both targets for miR-320a-3p.
Overexpression of miR-320-3p did not signiﬁcantly aﬀect
CYP17A1 mRNA levels but inhibition enhanced levels of
both mRNAs; this implies that CYP17A1 is already under
maximal inhibition at the miR-320-3p target site.
CYP17A1 determines relative ﬂow of steroid biosynthesis
through the 17-hydroxy and 17-deoxy pathways. An inﬂu-
ence here might aﬀect mineralocorticoid-glucocorticoid bal-
ance. Like most miRNAs characterised to date, miR-320-3p
has been reported to have multiple mRNA targets and regu-
late diﬀerent pathways in diﬀerent cell types. For example, it
has been implicated as a tumor suppressor in leukaemia [36]
but has also been associated with a detrimental eﬀect in cere-
bral ischaemia [37].
These results show the potential for several miRNAs to
modulate corticosteroidogenesis at the majority of relevant
loci. It is not possible to ascertain from these data whether
the overall eﬀect is due to several small individual eﬀects or
whether action at one locus predominates. We believe there
are many more miRNA-mediated eﬀects on this pathway
than have been identiﬁed thus far, and it may be that the
individual miRNA eﬀects we have investigated here are not
the most signiﬁcant. This is borne out by the fact that
qRT-PCR analysis of speciﬁc miRNA levels in the Dicer1
knockdown cells showed no signiﬁcant reduction on the
levels of the miRNAs miR-125a-5p, miR-125b-5p, miR-
134-3p, miR-320a-3p, and miR-495-3p relative to controls
(data not shown). While the Dicer1 knockdown experiments
were not designed with the intention of analysing individual
miRNA levels, or powered accordingly, it is tempting to
speculate that other miRNAs undergoing a greater dynamic
shift as a result of Dicer1 knockdown will emerge as those
most responsible for the observed changes in phenotype.
Importantly, if miRNAs are to be incorporated into the
existing model of control, more information on the control
of their own production is required. For example, it was
previously shown that miR-21 levels increase in H295R cells
following angiotensin II stimulation [10]. It must also be
emphasised that the H295R cell line is derived from neo-
plastic tissue with an atypical steroid proﬁle [24]. Also,
in dispersed cell experiments, the strict zonal constraints
on function and gene expression of the intact gland (e.g.,
the zonally distinct expressions of CYP11B1 and CYP11B2)
are absent. Nevertheless, the H295R cell has proved a valu-
able guide to in vivo adrenal physiology [24].
There is obvious interest in assessing the signiﬁcance
of such miRNA repression in vivo. We compared the
expression proﬁles of miRNAs in normal adrenal and
APA tissue and identiﬁed diﬀerential expression of ﬁve
miRNAs, in agreement with previous studies [8, 17–23].
miR-125a-5p expression was lower in APA. APA secretes
high levels of aldosterone, and the study described above
showed CYP11B2 to be aﬀected by this miRNA. However,
its clustered miRNAs were each more abundant in APA
tissue than in normal adrenal tissue. Previous studies
report reduced CYP17A1 expression in APA [38]. Our
study has shown a high level of miR-320a-3p in the
carcinoma-derived H295R cell line and its potency as a
CYP17A1 regulator. miRNA targeting of transcription
may be a common feature of this condition.
In summary, by manipulating their levels, we have
shown that miRNAs aﬀect the expression of multiple corti-
costeroidogenic genes and thereby aﬀect the steroid proﬁle
at multiple points. Corticosteroidogenic gene sequences
include 3′UTR sites that enable their posttranscriptional
regulation by speciﬁc miRNAs, as demonstrated here for
CYP11B2, CYP11A1, and CYP17A1. Importantly, a miRNA
which aﬀects aldosterone synthesis and another that aﬀects
CYP17A1 are expressed at diﬀerent levels in normal adre-
nal and APA tissue suggesting relevance to this form of
adrenal pathology.
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